ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Up 61.2% in February

ABVC BioPharma, Inc. (NASDAQ:ABVC) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 415,800 shares, an increase of 61.2% from the February 13th total of 257,900 shares. Currently, 3.7% of the shares of the company are sold short. Based on an average trading volume of 575,900 shares, the short-interest ratio is currently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ABVC BioPharma stock. Avantax Planning Partners Inc. raised its position in ABVC BioPharma, Inc. (NASDAQ:ABVC) by 269.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 143,968 shares of the company’s stock after buying an additional 104,968 shares during the period. Avantax Planning Partners Inc. owned about 1.11% of ABVC BioPharma worth $85,000 at the end of the most recent quarter. Institutional investors own 11.38% of the company’s stock.

ABVC BioPharma Price Performance

Shares of ABVC stock opened at $0.65 on Monday. The business has a fifty day moving average of $0.57 and a 200 day moving average of $0.58. ABVC BioPharma has a 1 year low of $0.40 and a 1 year high of $1.73. The firm has a market capitalization of $8.38 million, a price-to-earnings ratio of -0.75 and a beta of 0.67.

About ABVC BioPharma

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients.